Dave Grayzel
Director/Board Member chez AEROVATE THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Dave S.
Grayzel is the founder of Ataxion, Inc. (2013), Annovation BioPharma, Inc. (2011), Arteaus Therapeutics LLC (2011), Surface Oncology, Inc. (2014), and Acera School (2009).
He was also the founder of Cadent Therapeutics, Inc., Q32 Bio, Inc. (Massachusetts), and Q32 Bio, Inc. Dr. Grayzel's current job(s) included being an Independent Director at Affinia Therapeutics, Inc. (since 2020), an Independent Director at Aerovate Therapeutics, Inc. (since 2020), a Partner at Atlas Venture Advisors, Inc. (since 2010), a Partner at Atlas Venture Life Science Advisors LLC (since 2014), and a Member of the Tri-Institutional Therapeutics Discovery Institute, Inc. and One Brave Idea, Inc.Dr. Grayzel's former job(s) included being the Chief Executive Officer & Director of Ataxion, Inc. (founded in 2013), the Chief Executive Officer of Annovation BioPharma, Inc. (2011-2015), the Chief Executive Officer of Arteaus Therapeutics LLC (2011-2014), the Chairman of Surface Oncology, Inc. (2015-2017), a Director of Acera School (since 2009), the Director of Corporate Development at Dyax Corp.
(2000-2002), the Curriculum Director at Stanford Health Care, a Director of Xilio Therapeutics, Inc. (2018-2021), a Director of Delinea, Inc. (United States) (2015-2017), and the VP-Clinical Development & Medical Affairs at Infinity Pharmaceuticals, Inc. (2002-2010).
He was also a Principal at Quartet Medicine, Inc.Dr. Grayzel's education includes an undergraduate degree from Stanford University and a doctorate degree from Harvard Medical School (conferred in 1997).
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
02/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Dave Grayzel
Sociétés | Poste | Début |
---|---|---|
AEROVATE THERAPEUTICS, INC. | Director/Board Member | 01/08/2020 |
Tri-Institutional Therapeutics Discovery Institute, Inc.
Tri-Institutional Therapeutics Discovery Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The private company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg. | Corporate Officer/Principal | - |
Atlas Venture Life Science Advisors LLC
Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 01/01/2014 |
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Consultant / Advisor | - |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Director/Board Member | 01/03/2020 |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Founder | - |
One Brave Idea, Inc.
One Brave Idea, Inc. Miscellaneous Commercial ServicesCommercial Services One Brave Idea, Inc. operates a science innovation center. The private company is based in New York. | Corporate Officer/Principal | - |
Acera School | Founder | 01/01/2009 |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 01/06/2010 |
Anciens postes connus de Dave Grayzel
Sociétés | Poste | Fin |
---|---|---|
░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Dave Grayzel
Stanford University | Undergraduate Degree |
Harvard Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
INFINITY PHARMACEUTICALS, INC. | Health Technology |
XILIO THERAPEUTICS, INC. | Health Technology |
AEROVATE THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 17 |
---|---|
Dyax Corp.
Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Annovation BioPharma, Inc.
Annovation BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Annovation BioPharma, Inc. develops pharmaceutical products in the field of anesthesia, sedation and sleep. It is developing a rapid-acting anesthesia called Rapidate. The firm's novel agents are designed to allow more precise control of anesthesia and enable safer treatment of patients undergoing surgical procedures. The company was founded in 2009 by Nicholas Barker and is headquartered in Parsippany, NJ. | Health Technology |
Arteaus Therapeutics LLC
Arteaus Therapeutics LLC BiotechnologyHealth Technology Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Health Services |
Stanford Health Care
Stanford Health Care Hospital/Nursing ManagementHealth Services Stanford Health Care provides healthcare services. It services includes cardiac care, cancer treatment, neurosciences, surgery and organ transplants. The company was founded in 1956 and is headquartered in Stanford, CA. | Health Services |
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Health Technology |
Ataxion, Inc.
Ataxion, Inc. BiotechnologyHealth Technology Ataxion, Inc. develops novel therapies for rare, debilitating, and underserved neurologic diseases. It focuses on orphan genetic disorders termed hereditary ataxias. It was founded by Josh Resnick and David Grayzel in April 2013 and is headquartered in Cambridge, MA. | Health Technology |
Quartet Medicine, Inc.
Quartet Medicine, Inc. BiotechnologyHealth Technology Quartet Medicine, Inc. is a biotechnology company that develops treatments for chronic pain and inflammation by restoring tetrahydrobiopterin homeostasis inneuronal and inflammatory cells. Its drug discovery efforts are fully structurally enabled and are focused on demonstrating changes in BH4-related biomarkers that correlate with drug pharmacokinetics and efficacy in preclinical animal models. The company was founded by Kevin Pojasek, Kai Johnsson, and Clifford Woolf in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Acera School | |
Tri-Institutional Therapeutics Discovery Institute, Inc.
Tri-Institutional Therapeutics Discovery Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The private company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg. | Commercial Services |
Atlas Venture Life Science Advisors LLC
Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Delinea, Inc. (United States)
Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ. | Health Technology |
One Brave Idea, Inc.
One Brave Idea, Inc. Miscellaneous Commercial ServicesCommercial Services One Brave Idea, Inc. operates a science innovation center. The private company is based in New York. | Commercial Services |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Health Technology |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |